Mazdutide (10 mg Vial) Dosage Protocol

Educational reference for reconstitution and weekly administration of Mazdutide (IBI362), a dual GLP-1/glucagon receptor agonist investigated in clinical trials for weight management and type 2 diabetes treatment.

Dosing & Reconstitution Guide

Educational resource for reconstitution procedures and weekly dosing

Standard Titration Protocol (3.0 mL = ~3.33 mg/mL)

Timeframe	Weekly Dose	Insulin Units	Volume (mL)
Weeks 1–4	2.5 mg	75 units	0.75 mL
Weeks 5–8+	5 mg	150 units	1.50 mL

Frequency: Once weekly via subcutaneous injection

Advanced/High-Dose Protocol (2.0 mL = 5.0 mg/mL)

For accelerated dosing, reconstitute with 2.0 mL to achieve 5.0 mg/mL concentration:

Weeks	Weekly Dose	Units	Volume
1–4	5 mg	100 units	1.00 mL
5–8	7.5 mg	150 units	1.50 mL
9–12+	10 mg	200 units	2.00 mL

Caution: Doses exceeding 6 mg weekly increase gastrointestinal side effect risk and require clinical oversight. Split injections greater than 3.0 mL total volume into two separate sites.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with sterile syringe
2. Inject slowly down vial wall (avoid foaming)
3. Gently swirl until dissolved—do not shake vigorously
4. Label with date and refrigerate at 2–8 °C (35.6–46.4 °F) protected from light

How This Works

The dual agonist architecture activates both GLP-1 and glucagon signaling pathways simultaneously. This combination delivers glucose homeostasis regulation alongside metabolic acceleration—distinguishing it from single-target GLP-1 therapeutic agents. Phase 2 research demonstrated 6.7–11.3% body weight reduction at 3–6 mg weekly dosages over 24 week durations. Phase 3 trials have reported sustained 11–14% weight loss with 4–6 mg maintenance dosing over 48 week periods.

Potential Benefits & Side Effects

Findings from clinical trial research literature.

Reported Benefits

• 6–14% weight reduction (clinical trial range)
• Approximately 1.7% HbA1c improvement in type 2 diabetes cohorts
• Approximately 7% concurrent weight loss in diabetic populations
• Improved lipid profiles and glucose control
• Once-weekly dosing convenience

Common Adverse Effects

• Gastrointestinal: Nausea, vomiting, diarrhea, constipation (typically mild-to-moderate, diminishing over time)
• Injection site: Redness, swelling, mild discomfort
• Mitigation: Gradual titration significantly improves tolerability

Injection Technique

General subcutaneous administration guidance from clinical protocols.

1. Clean vial stopper and injection site with alcohol swabs; air-dry completely
2. Use aseptic technique throughout
3. Pinch skinfold; insert needle at 45–90° into subcutaneous fatty tissue
4. Do not aspirate for subcutaneous administration
5. Inject slowly over 5–10 seconds
6. Apply gentle pressure post-injection; do not rub
7. Rotate sites: abdomen (2+ inches from navel), thighs, upper arms
8. For volumes exceeding 3 mL, divide into two injections at separate sites

Important Notes

Practical considerations for consistency and safety protocols.

• Use new sterile insulin syringe for each weekly injection
• Rotate injection sites systematically to prevent lipoatrophy and irritation
• Allow reconstituted vial to reach room temperature before withdrawing to reduce viscosity
• Document dose, site, and side effects for protocol optimization
• This guidance is for research/educational purposes only; not medical advice

Storage Requirements

• Lyophilized: −20 °C (−4 °F) or below; protect from moisture and light
• Reconstituted: 2–8 °C (35.6–46.4 °F); use bacteriostatic water for multi-dose stability
• Critical: Never freeze reconstituted solution; avoid freeze–thaw cycles
• Discard: After 28 days or if cloudiness/particulates appear

Supply Calculation (8–16 Week Protocol)

Duration	Vials Needed	Syringes	Bacteriostatic Water	Alcohol Swabs
8 weeks	3 vials	8 syringes	1 × 10 mL bottle	16 swabs
12 weeks	5 vials	12 syringes	2 × 10 mL bottles	24 swabs
16 weeks	7 vials	16 syringes	3 × 10 mL bottles	32 swabs

References